INFINIUM Stock Overview
Engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infinium Pharmachem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹319.00 |
| 52 Week High | ₹392.50 |
| 52 Week Low | ₹178.05 |
| Beta | 0 |
| 11 Month Change | 3.32% |
| 3 Month Change | 64.43% |
| 1 Year Change | 30.20% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 331.66% |
Recent News & Updates
Recent updates
Investors Still Aren't Entirely Convinced By Infinium Pharmachem Limited's (NSE:INFINIUM) Earnings Despite 38% Price Jump
Sep 20
Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)
Aug 04Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Jun 12Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Nov 06Shareholder Returns
| INFINIUM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | 0.3% |
| 1Y | 30.2% | 40.5% | 27.3% |
Return vs Industry: INFINIUM underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: INFINIUM exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| INFINIUM volatility | |
|---|---|
| INFINIUM Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: INFINIUM's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: INFINIUM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 118 | Sanjaykumar Patel | www.infiniumpharmachem.com |
Infinium Pharmachem Limited engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. The company provides iodine derivatives and iodine based molecules / APIs / Iodination reaction based bulk drugs. It also provides potassium iodide and iodate, sodium iodide, iodine, povidone, and iodoform products.
Infinium Pharmachem Limited Fundamentals Summary
| INFINIUM fundamental statistics | |
|---|---|
| Market cap | ₹4.44b |
| Earnings (TTM) | ₹94.99m |
| Revenue (TTM) | ₹1.57b |
46.7x
P/E Ratio2.8x
P/S RatioIs INFINIUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INFINIUM income statement (TTM) | |
|---|---|
| Revenue | ₹1.57b |
| Cost of Revenue | ₹1.24b |
| Gross Profit | ₹328.42m |
| Other Expenses | ₹233.43m |
| Earnings | ₹94.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.83 |
| Gross Margin | 20.90% |
| Net Profit Margin | 6.05% |
| Debt/Equity Ratio | 24.0% |
How did INFINIUM perform over the long term?
See historical performance and comparison